search
Back to results

A Single-blind RCT to Investigate the Effect of a Novel Herbal Patch for the Treatment of PF

Primary Purpose

Plantar Fasciitis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Hong Kong
Study Type
Interventional
Intervention
CDAM
Sponsored by
Chinese University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Plantar Fasciitis focused on measuring Plantar Fasciitis, Herbal Patch

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female with age 18-65
  • Unilateral or bilateral
  • Heel pain for more than 6 weeks' duration
  • VAS score ≥ 5
  • Signed informed consent.

Exclusion Criteria:

  • Known chronic disease or receiving long-term medications affecting bone metabolism including BPs
  • Contraindication to alendronate therapy such as poor dental fitness
  • ACL injury less than 6 weeks
  • Injury on duty cases
  • Patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months
  • Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury)
  • Chondral lesion with concomitant intervention
  • Presence of X-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts
  • Neurological deficit
  • Pregnant or breastfeeding
  • Inability to give informed consent

Sites / Locations

  • Prince of Wales Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

CDAM group

Untreated group

Arm Description

Patients receive the CDAM patch and a standard home stretching exercise program

Patients receive a standard home stretching exercise program

Outcomes

Primary Outcome Measures

Foot Function Index (FFI) questionnaire
The FFI consists of 23 self-reported items divided into three subscales: limitation, pain and disability. The items are scored on a 10-point Likert scale. For each subscale, the raw score is transformed to a 100-point score, with higher score indicating worse limitation / pain / disability. The total score of FFI is the mean of the subscale scores. The Taiwan Chinese version of FFI has been validated.
Foot Function Index (FFI) questionnaire
The FFI consists of 23 self-reported items divided into three subscales: limitation, pain and disability. The items are scored on a 10-point Likert scale. For each subscale, the raw score is transformed to a 100-point score, with higher score indicating worse limitation / pain / disability. The total score of FFI is the mean of the subscale scores. The Taiwan Chinese version of FFI has been validated.
Foot Function Index (FFI) questionnaire
The FFI consists of 23 self-reported items divided into three subscales: limitation, pain and disability. The items are scored on a 10-point Likert scale. For each subscale, the raw score is transformed to a 100-point score, with higher score indicating worse limitation / pain / disability. The total score of FFI is the mean of the subscale scores. The Taiwan Chinese version of FFI has been validated.

Secondary Outcome Measures

Full Information

First Posted
October 14, 2022
Last Updated
August 6, 2023
Sponsor
Chinese University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT05584046
Brief Title
A Single-blind RCT to Investigate the Effect of a Novel Herbal Patch for the Treatment of PF
Official Title
Effect of a Novel Herbal Patch for the Treatment of Plantar Fasciitis - A Single-blind Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Disorders and injuries of tendons and ligaments are some of the most diagnosed musculoskeletal (MS) disorders clinically. Nearly half of the 33 million MS disorders reported in the United States each year are tendon and ligament injuries. Although most of such injuries are non-fatal, they are severely debilitating, resulting in significant reduction in patient's quality of life, loss of productivity, and considerable costs to the healthcare system. Among all tendon and ligament disorders and injuries, tendon and ligament overuse disorders are the most common and incapacitating ones. Tendinopathy is a painful tendon overuse disorder, which increases with population aging. It has been estimated that about 30% of consultations for MS complaints in a general practice were related to tendinopathy. The affected tendon is presented with local tenderness, swelling and pain, causing physical disability of the affected individual. The affected tendon degenerates and finally ruptures. Common sites of tendinopathy include supraspinatus, common wrist extensor, flexor tendon, patellar tendon, and Achilles tendon. The outcomes of both conservative treatments and surgeries are not satisfactory, with recurrent pain and tendon retear after surgery. Plantar fasciitis is a chronic painful, degenerative condition of the plantar fascia. It is caused by repetitive traumas at its origin on the calcaneus. Plantar fascia is a thick, ribbon-like fibrous ligament that connects the medial calcaneal tubercle to the heads of the metatarsal bones. It contributes to the support of the foot arch by acting as a tie-rod, where it undergoes tension when the foot bears weight. Therefore, although plantar fascia is anatomically defined as a ligament, it functions similar to a tendon. This study aims to conduct a randomized controlled study to test the efficacy of CDAM patch for the treatment of plantar fasciitis in patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plantar Fasciitis
Keywords
Plantar Fasciitis, Herbal Patch

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Single
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CDAM group
Arm Type
Experimental
Arm Description
Patients receive the CDAM patch and a standard home stretching exercise program
Arm Title
Untreated group
Arm Type
No Intervention
Arm Description
Patients receive a standard home stretching exercise program
Intervention Type
Other
Intervention Name(s)
CDAM
Intervention Description
Novel drugs such as Traditional Chinese Medicine (TCM) formula that can suppress inflammation may augment tissue healing and reduce activity-related pain in patients suffering from plantar fasciitis. Our team has experiences of using TCM for the treatment of plantar fasciitis. Based on our previous experience, our group has developed a new proprietary topical TCM herbal formula, CDAM, containing Carthami Flos , Dipsaci Radix , Aconiti Lateralis Radix Praeparata and Herba Menthae for the treatment of plantar fasciitis.
Primary Outcome Measure Information:
Title
Foot Function Index (FFI) questionnaire
Description
The FFI consists of 23 self-reported items divided into three subscales: limitation, pain and disability. The items are scored on a 10-point Likert scale. For each subscale, the raw score is transformed to a 100-point score, with higher score indicating worse limitation / pain / disability. The total score of FFI is the mean of the subscale scores. The Taiwan Chinese version of FFI has been validated.
Time Frame
Change from baseline FFI at 3 weeks
Title
Foot Function Index (FFI) questionnaire
Description
The FFI consists of 23 self-reported items divided into three subscales: limitation, pain and disability. The items are scored on a 10-point Likert scale. For each subscale, the raw score is transformed to a 100-point score, with higher score indicating worse limitation / pain / disability. The total score of FFI is the mean of the subscale scores. The Taiwan Chinese version of FFI has been validated.
Time Frame
Change from baseline FFI at 6 weeks
Title
Foot Function Index (FFI) questionnaire
Description
The FFI consists of 23 self-reported items divided into three subscales: limitation, pain and disability. The items are scored on a 10-point Likert scale. For each subscale, the raw score is transformed to a 100-point score, with higher score indicating worse limitation / pain / disability. The total score of FFI is the mean of the subscale scores. The Taiwan Chinese version of FFI has been validated.
Time Frame
Change from baseline FFI at 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female with age 18-65 Unilateral or bilateral Heel pain for more than 6 weeks' duration VAS score ≥ 5 Signed informed consent. Exclusion Criteria: Known chronic disease or receiving long-term medications affecting bone metabolism including BPs Contraindication to alendronate therapy such as poor dental fitness ACL injury less than 6 weeks Injury on duty cases Patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury) Chondral lesion with concomitant intervention Presence of X-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts Neurological deficit Pregnant or breastfeeding Inability to give informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick Shu-hang YUNG
Phone
+852 3505 2728
Email
patrickyung@cuhk.edu.hk
Facility Information:
Facility Name
Prince of Wales Hospital
City
Sha Tin
Country
Hong Kong

12. IPD Sharing Statement

Learn more about this trial

A Single-blind RCT to Investigate the Effect of a Novel Herbal Patch for the Treatment of PF

We'll reach out to this number within 24 hrs